Phase IIIb retrospective study of Ajovy shows efficacy in migraine.

Data presentations at AHS included eight abstracts examining real-world use of Ajovy across different patient populations and clinical circumstances. The US retrospective chart review study examined data from electronic medical records of 55 adult patients (age 18 and older) from the Dent Neurologic Institute, a multi-location practice in New York, who used Ajovy for preventive migraine treatment and concomitant gepants for acute migraine treatment between January 1, 2020 and May 1, 2021.

Data were collected on patients with chronic and episodic migraine. Patients were on a gepant therapy for one or more months pre- and post-initiation of Ajovy as add-on therapy. Patients with three or more measurements of monthly migraine days (MMD) were included in the analysis: one at the pre-index date (gepant initiation), one at index (Ajovy initiation), and one at the post-index period (gepant + Ajovy).

At the time of Ajovy initiation, patients had an average (standard deviation) of 15.8 (7.4) MMD. The average time from the index date to the last visit was 9.4 (4.5) months. The average change in MMD from the index to the post-index date was -6.5 (1.0) days, representing a 41.1% reduction. Five patients (9.1%) had adverse events post-index; 3 injection site reactions, 1 uveitis and 1 upset stomach.

In an additional poster presentation, results of a subgroup analysis from the Phase IIIb FOCUS study examining the use of Ajovy in patients with difficult-to-treat migraine and comorbid obesity were reported. The real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted. The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.